1. Home
  2. NLY vs EXAS Comparison

NLY vs EXAS Comparison

Compare NLY & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Annaly Capital Management Inc.

NLY

Annaly Capital Management Inc.

HOLD

Current Price

$22.97

Market Cap

16.3B

Sector

Real Estate

ML Signal

HOLD

Logo Exact Sciences Corporation

EXAS

Exact Sciences Corporation

HOLD

Current Price

$102.40

Market Cap

19.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NLY
EXAS
Founded
1996
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Medical Specialities
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
16.3B
19.3B
IPO Year
1997
N/A

Fundamental Metrics

Financial Performance
Metric
NLY
EXAS
Price
$22.97
$102.40
Analyst Decision
Buy
Buy
Analyst Count
11
19
Target Price
$23.55
$84.27
AVG Volume (30 Days)
9.1M
2.4M
Earning Date
01-28-2026
02-18-2026
Dividend Yield
12.17%
N/A
EPS Growth
80.25
N/A
EPS
2.92
N/A
Revenue
$2,304,722,000.00
$3,082,033,000.00
Revenue This Year
$166.06
$19.40
Revenue Next Year
$9.61
$13.54
P/E Ratio
$7.88
N/A
Revenue Growth
84.69
14.47
52 Week Low
$16.60
$38.81
52 Week High
$24.52
$102.66

Technical Indicators

Market Signals
Indicator
NLY
EXAS
Relative Strength Index (RSI) 43.52 74.75
Support Level $23.56 $102.12
Resistance Level $24.52 $102.59
Average True Range (ATR) 0.49 0.31
MACD -0.06 -0.40
Stochastic Oscillator 6.49 63.83

Price Performance

Historical Comparison
NLY
EXAS

About NLY Annaly Capital Management Inc.

Annaly Capital Management Inc is an American mortgage real estate investment trust. Its business objective is to generate net income for distribution to its stockholders and optimize its returns through prudent management of its diversified investment strategies. The company's reportable operating segments are; the Agency segment, which invests in Agency mortgage-backed securities collateralized by residential mortgages; the Residential Credit segment, which invests in non-Agency residential whole loans and securitized products within the residential and commercial markets; the Mortgage Servicing Rights segment; and Corporate & Other. Maximum revenue for the company is generated from its Agency segment.

About EXAS Exact Sciences Corporation

Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.

Share on Social Networks: